NASDAQ
4.31USD
-0.09 (-2.05%)
We have scored 6 news catalysts on AN2 Therapeutics, Inc. (ANTX) over the past 12 months. The biggest single-day move next to one of them came Mar 9, 2026, when ANTX closed +84.2%: “AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?”. Coverage across the window leans positive (average ticker sentiment +0.40). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
155.9M
P/E
—
EPS
—
Beta
-0.98
52W range
1-7.19
Day range
4.25–4.41
Open
4.41
Prev close
4.40
Volume
54.8K
Avg volume
284K
Dividend
0.00
IPO
2022-03-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about AN2 Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ANTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
